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Background. Endothelial Microparticles (EMPs) are small vesicles shed from activated or apoptotic endothelial cells and involved
in cellular cross-talk. Whether EMP immunophenotypes vary according to stimulus in Diabetes Mellitus (DM) is not known. We
studied the cellular adhesion molecule (CAM) proﬁle of circulating EMPs in patients with and without Diabetes Mellitus type 2,
who were undergoing elective cardiac catheterization. Methods and Results. EMPs were analyzed by ﬂow cytometry. The absolute
median number of EMPs (EMPs/μL) speciﬁc for CD31, CD105, and CD106 was signiﬁcantly increased in the DM population. The
ratio of CD62E/CD31 EMP populations reﬂected an apoptotic process. Conclusion. Circulating CD31+, CD105+, and CD106+
EMPs were signiﬁcantly elevated in patients with DM. EMPs were the only independent predictors of DM in our study cohort.
In addition, the EMP immunophenotype reﬂected an apoptotic process. Circulating EMPs may provide new options for risk
assessment.
1.Introduction
Endothelial microparticles (EMPs) are an emerging marker
of endothelial cell (EC) dysfunction, and their circulating
numbers are elevated in a number of pathologic states
including cardiovascular disease [1]. EMPs contain mem-
brane, cytoplasmic, and nuclear constituents, characteristic
of their precursor cells that confer to EMPs the properties
of circulating multifunctional eﬀectors, promoting inﬂam-
mation of the arterial wall and thrombogenicity through
cellular cross-talk [2]. Leukocyte adhesion and migration
are dependent on a range of cellular adhesion molecules
(CAMs) that are up regulated in the endothelium during
atherosclerosis [3]. Because microparticles are fragments
of EC membranes, they also express CAMs. MiRNAs are
also contained in circulating microparticles (MPs) and may
inﬂuence vascular homeostasis [4]. Additionally, studies
demonstrate that, EMPs correlate in vivo with indices of
EC dysfunction, the presence of coronary artery disease and
with the complications of Diabetes Mellitus type 2 (DM)
[5, 6].
DM is a major risk factor for cardiovascular morbidity
and mortality, and the proportion of cardiovascular disease
attributable to DM has increased over the past 50 years
[7]. It is well established that endothelial dysfunction and
inﬂammation are key features of DM and are independent
of other cardiovascular risk factors [8]. In type I DM the
procoagulant potential of MPs is correlated with the degree
of glycemic control, and elevated EMP levels are predictive
forthe presenceandseverity of coronaryarterylesions [6,9].
Plaque rupture and acute coronary thrombosis may also
be associated with the activation of tissue factor from its
encryptedformonMPs[10,11].Inaddition,plaquestability
and high risk coronary lesions correlate with the level of
circulating EMPs and the expression of speciﬁc CD antigens
[12].
Studies suggest that MPs produced via activating stimuli
have diﬀerent protein expression patterns from those pro-
ducedviaapoptosis.Thepresentstudyaddressesthehypoth-
esis that DM produces EMPs that vary in immunopheno-
type. Using a ﬂow cytometric approach, we compared the
CAM composition of diﬀerent populations of EMPs isolated2 Mediators of Inﬂammation
from DM patients who were undergoing elective cardiac
catheterization.
2. Methods
2.1. Clinical Study Population. We performed a cross-
sectional study that prospectively and sequentially included
40 patients (20 diabetics and 20 nondiabetics) under-
going cardiac catheterization. All catheterization proce-
d u r e sw e r ee l e c t i v ea n df o rs u s p e c t e dc o r o n a r ya r t e r y
disease. The following clinical information was collected
from all study subjects: age, sex, body mass index, blood
pressure, total cholesterol, blood glucose, and history of
smoking. Diabetes was deﬁned by a fasting plasma glu-
cose ≥126mg/dL (7.0mmol/L), nonfasting plasma glu-
cose ≥200mg/dL (11.1mmol/L), or the individual cur-
rently being treated with insulin or an oral hypoglycemic
agent. BMI was calculated as the ratio of weight-to-height
squared; resting brachial blood pressure was measured by an
automated sphygmomanometer; and hypertension (HTN)
was deﬁned as a resting blood pressure >140/90mmHg
and/or the presence of antihypertensive treatment. Blood
lipids and glucose were measured by enzymatic methods,
and hypercholesterolemia was deﬁned by total cholesterol
>200mg/dL and/or the presence of lipid lowering drug
treatment (NCEP Circ 2002 106). Current smoking was
deﬁned as daily consumption of ≥1 cigarette daily for ≥3
months. All patients were fasting for >12 hours. Recent
laboratory data and drug therapy were obtained from chart
review. The study was approved by the Winthrop-University
Hospital IRB committee.
2.2.BloodSampling. Arterialbloodwascollectedviafemoral
artery catheter into 3.2% trisodium citrate (Becton Dickin-
son, San Jose CA). Platelet-free plasma was obtained and
subjected to centrifugation at 13,000g for 45 minutes. The
microparticle pellets were resuspended in 100μL of PBS and
stored at −80
◦C until use in ﬂow cytometry experiments.
Samples were processed within one hour after collection and
freeze-thawed only once immediately before ﬂow cytometric
analysis.
2.3. Electron Microscopy. To assess whether intact MPs were
present after plasma preparation, the total number of pellet-
derived MPs was assessed with electron microscopy. Pellet-
derived MPs were ﬁxed in 4% glutaraldehyde, 0.1M sodium
cacodylate buﬀer, pH 7.4, postﬁxed in 1% buﬀered osmium
tetroxide, dehydrated in a graded series of ethanol, and
inﬁltrated in LX112 Epon Resin purchased from Ladd
(Burlington, VT). Thin sections were picked up on copper
formvar-coated grids, stained with lead citrate and uranyl
acetate, and analyzed on a Zeiss EM10 transmission electron
microscope.
2.4. Flow Cytometric Analysis. Brieﬂy, 3μL of a ﬂurochrome-
conjugated monoclonal antibody against one of the listed
CAMs (Table 1)p l u s5 0μL of prepared plasma were added
to tubes (2 antibodies/tube) that were preloaded with
ﬂuorescent TruCountTM bead lyophilized pellets (Becton
Dickinson Biosciences, San Jose, CA), as outlined previously
[13]. Calibration beads were obtained from Molecular
Probes (Eugene, OR). Monoclonal antihuman CD62E-
FITC, CD105-FITC, CD106-FITC, CD144-FITC, CD31-
FITC, CD41a-PE, and CD45-PE antibodies were obtained
from Ancell Co. (Bayport, MN). Analysis of EMPs was
performed using an FACS Canto Flow Cytometer (Becton
Dickinson Biosciences, San Jose, CA), operated at medium
ﬂow-rate setting, with log gain on light scatter and ﬂuores-
cence. Events with 0.2 to 1.0μm size on FS-SS graph were
gated as EMPs. Data from 5,000 events were acquired and
analyzed with the use of BD FACSDiva (version 4.1.2, Becton
Dickinson). All ﬂow cytometry experiments included EMP
samples labeled with single antibody conjugates incorporat-
ing the relevant ﬂuorochromes for compensation. The abso-
lute number of EMPs was enumerated from the appropriate
dot plot values entered into the following formula:
Absolute number of EMPs/mL
=#ofeventsinEMPregion(R2) ×total#ofbeadspertube/
#o fb e a d sc o l l e c t e d(R1) ×test volume

50μL

.
(1)
The total number of beads per tube is supplied by the
manufacturer and varies among lot numbers. To access
the method’s ability to distinguish EMPs from platelet
MPs, known quantities of pure EMPs from TNF-α-activated
human umbilical vein endothelial cell culture and platelet
MPsfromisolatedplateletsfromnormalsubjectsweremixed
together. Counts of EMPs and platelet MPs of the mixture
were the same as when measured independently. These
results support the speciﬁcity of the assay for detecting
EMPs. To test whether leukocyte MPs might be confused
with EMPs, the pan leukocyte marker anti-CD45 was
used. Negligible CD31+/CD41a+ EMPs were detected. No
signiﬁcant nonspeciﬁc binding of leukocyte MPs was noted.
2.5. IL-1 Assay. The concentration of IL-1β was measured by
bead array (BioRad Cat# 171B12832) using the BioPlex200
(BioRad, Hercules, CA). Brieﬂy, plasma was diluted 1 : 1
in commercial diluent and processed according to the
manufacturer’s instructions. Unknown concentrations were
obtained by extrapolation from a curve of known standards.
2.6. Statistical Analysis. Continuous variables were tested
for normal distribution with the Kolmogorov-Smirnov test.
The Wilcoxon Rank Sum test was used to compare the
study variables between DM patients and nondiabetics.
Correlation analyses were performed using the Spearman
rank coeﬃcient. Multiple linear regression analysis was
performed where indicated in order to identify independent
variables inﬂuencing the prediction of EMP changes in
peripheral blood. EMP numbers and data that were not
normally distributed are expressed as medians (interquartile
range or range). Statistical signiﬁcance was assumed when a
null hypothesis could be rejected at a P<. 05.Mediators of Inﬂammation 3
Table 1: EC-associated CAM panel for the analysis of EMPs.
Adhesion molecule Action Cell of origin Expression Counter-receptor Target cells
CD62 (E-selectin) Rolling Activated EC Activation L-Slectin, β2 integrins WBC
CD106 (VCAM-1) Adhesion EC Activation VLA-4 Mono’s, Lymphs
CD105 (Endoglin) Angiogenesis EC Constitutive CD105 EC
CD31 (PECAM-1) Adhesion EC, Pits, WBC Constitutive PECAM-1 EC, Pits, WBC
CD144 (VE-cadherin) Adhesion EC Constitutive CD144 EC
Table 2: The clinical characteristics of the 40 enrolled patients.
Parameter Diabetic Nondiabetic P-value
(n = 20) (n = 20)
Age (years) 63.7 ± 11.4 70.8 ± 11.5 .32
Sex
18 F (45%) 10 8 .75
22 M (55%) 10 12 .37
BMI (kg/m2) 33.5 ± 8.6 27.5 ± 5.1 .02
Hypertension 16 (80%) 16 (80%) .52
Blood Glucose 142.9 ± 55.1 105.8 ± 27 .0067
Total Cholesterol (mg/dL) 163 ± 37.9 176 ± 48.8 .49
Lipid lowering therapy 16 (80%) 15 (75%) .99
CAD 19 (95%) 15 (75%) .18
Current smoking 2 (15%) 1 (5%) .60
3. Results
3.1. Subject Characteristics. Subject demographics and clin-
ical characteristics of DM patients and controls are shown
in Table 2. DM patients had signiﬁcantly higher BMIs and
fasting plasma glucose. A signiﬁcant diﬀerence also existed
in age between the two groups.
3.2. Electron Microscopy. Plasma MPs are predominately
derived from platelets, erythrocytes, and monocytes, with
EMPs comprising the smallest circulating MP population
[14, 15]. Electron microscopy can be used for better char-
acterization of morphological features and visualization of
MPs. MP size varies between 0.2 and 1.0μm[ 16, 17]. We
performedtransmissionelectronmicroscopyonplatelet-free
plasma-derived pellets from both diabetic and nondiabetic
patients. Transmission electron micrographs of platelet-
free plasma pellet fractions at low and high magniﬁcation
demonstrated intact MPs of various sizes with cellular
organelle remnants (Figure 1). There were no morphological
or structural diﬀerences of MPs visualized between diabetic
and nondiabetic subjects.
3.3. Numbers and Immunophenotype of Circulating EMPs.
EMPs may express adhesion molecules speciﬁc for mature
endothelial cells (Table 1): examples are CD62E (E-selectin),
CD62P (P-selectin), and CD31. Because CD31 is also
expressed by platelet-derived MPs, EMP speciﬁcity was
ensured by the CD31+/CD41− phenotype (CD41 being the
platelet gpIIbIIIa complex found on platelets, megakary-
ocytes, and monocytes). EMPs also exhibit endothelial cell-
speciﬁc antigens such as CD105 (endoglin, a proliferation-
associated protein) and CD144 (VE-cadherin). In both
patients and controls, platelet microparticles (PMP) con-
stituted the largest proportion of total MPs. Comparable
but low numbers of leukocyte-derived MPs were found in
both populations. A known count of larger beads (Tru-
Count beads) acted as an internal standard and enabled
us to calculate the absolute number of EMPs per analyzed
volume of specimen (Figure 2). We found that the absolute
median number of EMPs speciﬁc for CD31, CD105, and
CD106 was signiﬁcantly increased in the DM population
(CD31+/41a− EMPs: 22238 to 157 × 104/μL[ D Mv e r s u s
control], P =.0006; CD105+ EMPs: 2200 to 390 × 103/μL,
P =.002; CD106+ EMPs: 4939 to 740 × 103/μL, P =
.001) (Figure 3). DM subjects also had elevated levels of
CD62E+ EMPs; however this was not signiﬁcant. There was
no signiﬁcant diﬀerence of CD144+ EMPs noted between
populations.
3.4. Apoptosis versus Activation. Studies suggest that MPs
producedviaactivatingstimulihavediﬀerentproteinexpres-
sion patterns from those produced via apoptosis; conse-
quentlyanalysisofEMPphenotypicproﬁlemayprovideclin-
ically useful information on the status of the endothelium.
The ratio of CD62E+/CD31+ EMP populations, rather than
their absolute numbers, has been described as a criterion
for distinguishing activation versus apoptosis. A ratio ≥10
identiﬁes activation while ratio ≤1.0 identiﬁes apoptosis.
Our data suggest that apoptosis is an important mechanism
for EMP release in the DM population.
3.5. Association of EMPs with Components of DM. The
release of EMPs into circulation makes their levels closely
associated with the degree of vascular damage. To identify
independent predictors for EMP elevation, we performed a
multivariate linear regression analysis including age, gender,
BMI, HTN, plasma cholesterol level, glucose, and EMP
phenotypes as independent variables. BMI levels tended to
be independently associated with CD31+ EMPs; however,
this relationship was not signiﬁcant. There was a positive
correlation between IL-1 levels and the number of CD 144+
EMPs (Figure 4).
There was no signiﬁcant diﬀerence in IL-1 levels between
the diabetic and nondiabetic group.4 Mediators of Inﬂammation
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Figure 1: Various sized microparticles were isolated from platelet-free plasma from a normal subject and analyzed by transmission electron
microscopy. (a–d) Smallest particles noted around 0.2μm in size. Note intact plasma membrane (pm) and various intracellular organelle
remnantsincludingPlateletmicroparticle(d).Noteabundanceofglycogengranules(gg),mitochondria(m),vacuole(v),andalphagranules
(ag). Scale bar = 0.1μm.
4. Discussion
We demonstrated that DM is associated with increased
levelsofcirculatingEMPs.Thiscorroboratespreviousstudies
wherelevelsofEMPswereassociatedwithmicroalbuminuria
and microvascular complications in patients with type I
diabetes,suggestingthatEMPscouldbeamarkerofdiabetes-
associated endothelial dysfunction [18, 19]. EMPs make
up just a small portion of the total circulating population
of microparticles. Utilizing electron microscopy we con-
ﬁrmed the presence of intact MPs with various intracellular
organelle remnants found in prepared plasma. Exosomes
and larger MPs (>1.0μm in size and often platelets, MP
aggregates, or apoptotic bodies) were excluded by our gating
protocol. Circulating EMPs are associated with the presence
of high-risk angiographic lesions, including eccentric type
II, multiple irregular, and lesions with thrombi; however
we found no signiﬁcant relation of EMP levels with the
presence or severity of CAD [9, 20]. Multivariate analysis
correcting for age, gender, HTN, hyperlipidemia, smoking,
and statin use identiﬁed EMPs as an independent predictor
for the presence of DM. A signiﬁcant diﬀerence was also
seen in age, BMI, and blood glucose between the two
groups but we did not observe an eﬀect of these variables
on EMP levels. In this cross-sectional study of patients
undergoing elective cardiac catheterization, we found that
circulating levels of CD31+, CD105+, and CD106+ EMPs
were signiﬁcantly increased in patients with DM compared
with nondiabetic control patients. Elevated species of EMPs
present in diabetic subjects were characterized by a con-
stitutive antigenic immunophenotype suggesting an apop-
totic mechanism of EMP generation in diabetic individuals
[21].
One of the earliest events in atherosclerosis is CAM-
mediated adhesion of circulating monocytes to intact acti-
vated endothelial cells [22, 23]. Despite the large body of
literature on the expression and function of CAMs, the
biological properties and function of the circulating form
of these molecules remain unclear [24, 25]. Accordingly,
analysis of EMP phenotypes provides insight into the nature
of endothelial injury. We identiﬁed a signiﬁcant elevation
of three EMP immunotypes in diabetic plasma. CD31+,
CD105+, and CD106+ EMP subsets are characterized by
CAMs integral to the atherothombotic process. Patients with
the metabolic syndrome have markedly elevated CD31+
(PECAM-1) EMPs [26]. Additionally, CD31 is an eﬃcient
signaling molecule related to angiogenesis, platelet function,
thrombosis, mechanosensing of endothelial cell response
to ﬂuid shear stress, and regulation of multiple stages of
leukocyte migration [27, 28]. Of note, the use of CD31Mediators of Inﬂammation 5
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Figure 2: Gating protocol. (a) Bivariant analysis eﬃciently distinguished EMPs from quantitation beads. (b) EMPs from activated EC culture
had negligible autoﬂuorescence on FITC/PE channels. (c) Two-color staining with CD41a enables CD31+ EMPs to be segregated from
platelet microparticles. (d) Logicle displays provide improved representation of the EMP population with minimal ﬂuorescence.
as a sole marker for EMP detection is controversial and
has not been consistently shown to distinguish EMPs from
PMPs. CD105 (endoglin) is a transmembrane glycoprotein
found in the vast majority of the microvessels in atheroma
and with a pronounced expression around the periphery
of the lipid core [29]. Vascular cell adhesion molecule-1
(VCAM-1, CD106) is expressed on activated endothelial
cells and participates in the inﬂammatory initiation and
progression of atherosclerotic plaques [30, 31]. We also
identiﬁed elevated levels of 62E+ (E-selectin) EMPs that
trended towards signiﬁcance. E-selectin is also expressed in
activated endothelium and was found to be an independent
p r e d i c t o ro fD M[ 32].
The immunophenotype of MPs depends on whether
they are released by cell activation or by apoptotic stimulus
[21]. Cellular apoptosis is associated with an increase in
cytosoliccalcium,withchangesinthetransmembranesteady
state leading to the cleavage of cytoskeleton ﬁlaments.
These phenomena result in the blebbing and shedding of
membrane-derived MPs into the extracellular ﬂuid [3]. In
vitro studies have shown that processes of apoptosis are
reﬂected by enhanced expression of constitutive antigens on
EMPs (e.g., CD31, CD105) and increased binding of annexin
V to EMPs. [33]. In contrast, activation of endothelial
cells without apoptosis does not aﬀect the expression of
constitutive markers, but signiﬁcantly increases the levels
of inducible antigens on EMPs (e.g., CD62E, CD106) [33,
34]. We found that circulating EMPs from diabetic patients
predominately expressed constitutive markers (CD31 and
CD105) as opposed to inducible markers. In addition, the
ratio of CD62E+/CD31+ populations, rather than their
absolute numbers, was used as a criterion for distinguishing
activation versus apoptosis. Both of these ﬁndings suggest
that ECs may release EMPs in an attempt to reverse
the apoptotic process by freeing the cell of unwanted
signaling molecules like proapoptotic caspase-3 and phos-
phatatidylserine. Alternatively, membrane shedding could
constitute a signaling entity to phagocytes and neighboring
cells. These results might be interpreted as an indication of
enhancedendothelial cellapoptosis, ratherthanactivationin
those having DM. Additionally, some EMP species increase
with augmented endothelial dysfunction and inﬂammation
as evidenced in our study by the correlation of CD144+
EMPs with IL-1.6 Mediators of Inﬂammation
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Figure 3: Diabetic patients had signiﬁcantly increased absolute number EMPs compared to controls. Box-and-whisker plot showing plasma
values in patients with and without DM: CD31+/CD41− EMP (a), CD 105+ EMP (b), and CD 106+ EMP (c). In these plots, lines within
boxes represent median values; the upper and lower lines of the boxes represent the 25th and 75th percentiles, respectively; the upper and
lower bars outside the boxes represent the 90th and 10th percentiles, respectively.
Asbiomarkers,EMPsallowaccesstoatypicallyinaccessi-
bletissue,theendothelium.ThisstudyfoundthatEMPswere
independentlyassociatedwiththepresenceofDMandreﬂect
immunophenotypes important to the atherothombotic pro-
cess. Therefore, EMPs may be a useful surrogate marker for
evaluating endothelial dysfunction and/or injury. There is a
paucity of information regarding the change in endothelial
function over time as it relates to diabetic control and
atherosclerotic burden. To help circumvent these problems
studies utilizing serial sampling should be performed in
diabetic patients thereby allowing each patient to serve as his
own biological control. In addition, the storage and freezing
ofplasmasamplesmightaﬀecttherelativelevelsofEMPsand
the reliability of the results compared to those obtained from
freshly isolated preparations. Consequently, protocols need
to be optimized for the clinical setting where ﬂow cytometry
cannot always be performed on the same day as specimen
collection. Caution should also be taken when extrapolating
laboratory experiments from the results of clinical studies,
because a given EMP type may be present with a variety of
compositions and biological behavioral patterns in vitro and
in vivo.Mediators of Inﬂammation 7
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Figure 4: Correlation plot and linear regression line between
CD144+ EMPs and the cytokine IL-1.
Atherosclerosis is a diﬀuse, multisystem, and chronic
inﬂammatory disease. Therefore, it is essential to assess
total vulnerability burden in subjects with a high likelihood
of developing cardiac events [35]. A quantitative method
for cumulative risk assessment of DM patients needs to
be developed that includes variables based on plaque,
blood, and myocardial vulnerability in the outcome. Serum
m a r k e r sl i k eE M P sm a yb eo n es u c hm a r k e ro f“ v u l n e r a b l e
blood” in patients at risk of cardiovascular events. Larger
prospective studies are needed to establish the incremental
value of EMP quantiﬁcation above established risk markers.
Improved knowledge of EMP composition, their biological
eﬀects, and the mechanisms leading to their clearance will
probably open new therapeutic approaches in the treatment
of atherosclerosis in DM.
References
[1] Z. Mallat, H. Benamer, B. Hugel, et al., “Elevated levels of shed
membrane microparticles with procoagulant potential in the
peripheral circulating blood of patients with acute coronary
syndromes,” Circulation, vol. 101, no. 8, pp. 841–843, 2000.
[2] C. M. Boulanger, A. S. Leroyer, N. Amabile, and A. Tedgui,
“Circulating endothelial microparticles: a new marker of
vascular injury,” Annales de Cardiologie et d’Angeiologie, vol.
57, no. 3, pp. 149–154, 2008.
[3] S. Blankenberg, S. Barbaux, and L. Tiret, “Adhesion molecules
and atherosclerosis,” Atherosclerosis, vol. 170, no. 2, pp. 191–
203, 2003.
[4] M. P. Hunter, N. Ismail, X. Zhang, et al., “Detection of
microRNA expression in human peripheral blood microvesi-
cles,” PLoS ONE, vol. 3, no. 11, article e3694, 2008.
[5] M. E. Tushuizen, R. Nieuwland, C. Rustemeijer, et al., “Ele-
vated endothelial microparticles following consecutive meals
are associated with vascular endothelial dysfunction in type 2
diabetes,” Diabetes Care, vol. 30, no. 3, pp. 728–730, 2007.
[6] H. Koga, S. Sugiyama, K. Kugiyama, et al., “Elevated levels
of VE-cadherin-positive endothelial microparticles in patients
with type 2 diabetes mellitus and coronary artery disease,”
Journal of the American College of Cardiology, vol. 45, no. 10,
pp. 1622–1630, 2005.
[ 7 ]C .S .F o x ,M .J .P e n c i n a ,P .W .F .W i l s o n ,N .P .P a y n t e r ,R .S .
Vasan, and R. B. D’Agostino, “Lifetime risk of cardiovascular
diseaseamongindividualswithandwithoutdiabetesstratiﬁed
by obesity status in the Framingham heart study,” Diabetes
Care, vol. 31, no. 8, pp. 1582–1584, 2008.
[ 8 ]J .E .D e a n ﬁ e l d ,J .P .H a l c o x ,a n dT .J .R a b e l i n k ,“ E n d o t h e l i a l
function and dysfunction: testing and clinical relevance,”
Circulation, vol. 115, no. 10, pp. 1285–1295, 2007.
[9] L. Bernal-Mizrachi, W. Jy, C. Fierro, et al., “Endothelial
microparticles correlatewith high-riskangiographic lesions in
acute coronary syndromes,” International Journal of Cardiol-
ogy, vol. 97, no. 3, pp. 439–446, 2004.
[10] B. Furie and B. C. Furie, “Mechanisms of thrombus forma-
tion,” New England Journal of Medicine, vol. 359, no. 9, pp.
938–949, 2008.
[11] Z. Mallat, B. Hugel, J. Ohan, G. Les` eche, J. M. Freyssinet, and
A. Tedgui, “Shed membrane microparticles with procoagulant
potential in human atherosclerotic plaques: a role for apopto-
sis in plaque thrombogenicity,” Circulation,v o l .9 9 ,n o .3 ,p p .
348–353, 1999.
[12] L. Bernal-Mizrachi, W. Jy, J. J. Jimenez, et al., “High levels of
circulating endothelial microparticles in patients with acute
coronary syndromes,” American Heart Journal, vol. 145, no. 6,
pp. 962–970, 2003.
[13] A. F. Tramontano, J. O’Leary, A. D. Black, R. Muniyappa,
M. V. Cutaia, and N. El-Sherif, “Statin decreases endothelial
microparticle release from human coronary artery endothelial
cells: implication for the Rho-kinase pathway,” Biochemical
and Biophysical Research Communications, vol. 320, no. 1, pp.
34–38, 2004.
[14] C. M. Boulanger, N. Amabile, and A. Tedgui, “Circulating
microparticles: a potential prognostic marker for atheroscle-
rotic vascular disease,” Hypertension, vol. 48, no. 2, pp. 180–
186, 2006.
[15] N. Amabile, A. P. Gu´ erin, A. Leroyer, et al., “Circulating
endothelial microparticles are associated with vascular dys-
functioninpatientswithend-stagerenalfailure,”Journalofthe
AmericanSocietyof Nephrology, vol. 16, no. 11, pp. 3381–3388,
2005.
[16] J. King, E. Syklawer, H. Chen, et al., “Lung endothelial
cells express ALCAM on released exosomes/microparticles,”
MicroscopyandMicroanalysis,vol.14,supplement2,pp.1520–
1521, 2008.
[17] V. Combes, A. C. Simon, G.E. Grau, et al., “In vitro generation
of endothelial microparticles and possible prothrombotic
activity in patients with lupus anticoagulant,” Journal of
Clinical Investigation, vol. 104, no. 1, pp. 93–102, 1999.
[18] M. Diamant, R. Nieuwland, R. F. Pablo, A. Sturk, J. W.
A. Smit, and J. K. Radder, “Elevated numbers of tissue-
factor exposing microparticles correlate with components of
the metabolic syndrome in uncomplicated type 2 diabetes
mellitus,” Circulation, vol. 106, no. 19, pp. 2442–2447, 2002.
[19] F. Sabatier, P. Darmon, B. Hugel, et al., “Type 1 and
type 2 diabetic patients display diﬀerent patterns of cellular
microparticles,” Diabetes, vol. 51, no. 9, pp. 2840–2845, 2002.
[20] S. Bernard, R. Loﬀroy, A. S´ erusclat, et al., “Increased levels
of endothelial microparticles CD144 (VE-Cadherin) positives8 Mediators of Inﬂammation
in type 2 diabetic patients with coronary noncalciﬁed plaques
evaluated by multidetector computed tomography (MDCT),”
Atherosclerosis, vol. 203, no. 2, pp. 429–435, 2009.
[21] J .J .Jimenez,W .Jy ,L.M.Mauro ,C.Soderland,L.L.Horstman,
and Y. S. Ahn, “Endothelial cells release phenotypically
and quantitatively distinct microparticles in activation and
apoptosis,” Thrombosis Research, vol. 109, no. 4, pp. 175–180,
2003.
[22] R. Ross, “Atherosclerosis—an inﬂammatory disease,” New
EnglandJournalofMedicine,vol.340,no.2,pp.115–126,1999.
[23] E. Galkina and K. Ley, “Vascular adhesion molecules in
atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 27, no. 11, pp. 2292–2301, 2007.
[24] B. A. Garcia, D. M. Smalley, H. Cho, J. Shabanowitz, K. Ley,
andD.F.Hunt,“Theplateletmicroparticleproteome,”Journal
of Proteome Research, vol. 4, no. 5, pp. 1516–1521, 2005.
[ 2 5 ]D .M .S m a l l e y ,K .E .R o o t ,H .C h o ,M .M .R o s s ,a n d
K. Ley, “Proteomic discovery of 21 proteins expressed in
human plasma-derived but not platelet-derived microparti-
cles,” Thrombosis and Haemostasis, vol. 97, no. 1, pp. 67–80,
2007.
[26] R. B. Arteaga, J. A. Chirinos, A. O. Soriano, et al., “Endothe-
lial microparticles and platelet and leukocyte activation in
patients with the metabolic syndrome,” American Journal of
Cardiology, vol. 98, no. 1, pp. 70–74, 2006.
[27] A. Woodﬁn, M. B. Voisin, and S. Nourshargh, “PECAM-1:
a multi-functional molecule in inﬂammation and vascular
biology,” Arteriosclerosis, Thrombosis, and Vascular Biology,
vol. 27, no. 12, pp. 2514–2523, 2007.
[28] B. L. Harry, J. M. Sanders, R. E. Feaver, et al., “Endothe-
lial cell PECAM-1 promotes atherosclerotic lesions in areas
of disturbed ﬂow in ApoE-deﬁcient mice,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 28, no. 11, pp. 2003–
2008, 2008.
[29] J. Krupinski, M. M. Turu, A. Luque, L. Badimon, and M.
Slevin, “Increased PrPC expression correlates with endoglin
(CD105) positive microvessels in advanced carotid lesions,”
Acta Neuropathologica, vol. 116, no. 5, pp. 537–545, 2008.
[30] P. Libby, “Inﬂammation in atherosclerosis,” Nature, vol. 420,
no. 6917, pp. 868–874, 2002.
[31] M. I. Cybulsky and M. A. Gimbrone Jr., “Endothelial expres-
sion of a mononuclear leukocyte adhesion molecule during
atherogenesis,” Science, vol. 251, no. 4995, pp. 788–791, 1991.
[32] J. B. Meigs, F. B. Hu, J. S. Perhanidis, D. Hunter, N. Rifai, and
J. E. Manson, “E-selectin genotypes and risk of type 2 diabetes
in women,” Obesity Research, vol. 13, no. 3, pp. 513–518, 2005.
[33] O. Morel, P. Ohlmann, E. Epailly, et al., “Endothelial cell
activationcontributestothereleaseofprocoagulantmicropar-
ticles during acute cardiac allograft rejection,” Journal of Heart
and Lung Transplantation, vol. 27, no. 1, pp. 38–45, 2008.
[34] G. N. Chironi, C. M. Boulanger, A. Simon, F. Dignat-George,
J. M. Freyssinet, and A. Tedgui, “Endothelial microparticles in
diseases,”CellandTissueResearch,vol.335,no.1,pp.143–151,
2009.
[35] M. Naghavi, P. Libby, E. Falk, et al., “From vulnerable plaque
to vulnerable patient: a call for new deﬁnitions and risk
assessment strategies: part II,” Circulation, vol. 108, no. 15, pp.
1772–1778, 2003.